Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Cancer Res. 2014 Mar 17;74(11):2962–2973. doi: 10.1158/0008-5472.CAN-13-2421

Fig. 2. Wnt7b expression and deletion in the MMTV-PyMT model.

Fig. 2

(A) End-point RT-PCR for Wnt7b from in flow-sorted dextran+, F4/80+ mouse macrophages from Wnt7btm2Amc/− (control, C) and Wnt7btm2Amc/−; Csf1r-icre (mutant, M) MMTV-PyMT tumors. (B) Genotyping PCR on peritoneal cells (PC) or in flow-sorted dextran+, F4/80+ macrophages from MMTV-PyMT tumors of the indicated genotypes. The PCR primers used do not amplify a product from the recombined Wnt7btm2Amc allele. (C) Relative Wnt7b mRNA expression in control (C) and mutant (M) MMTV-PyMT mammary tumors at premalignant (Hyperplasia and Adenoma, H/A), or malignant (early carcinoma, EC, and late carcinoma, LC) stages. Error bars are SEM. (D) Percentage of marker positive cells in control (MMTV-PyMT; Wnt7btm2Amc/−, C) and mutant (MMTV-PyMT; Wnt7btm2Amc/−; Csf1r-iCre, M) tumors combined from the 20–22 week range. Error bars are SEM.